Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives
Authors:
Open Access
- 5 March 2024
- journal article
- review article
- Published by Elsevier in Neurobiology of Disease
- Vol. 193, 106467
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Telethon (GGP19002)
- Ministero della Salute (GR-2018-12365358)
This publication has 100 references indexed in Scilit:
- Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2ACellular and Molecular Life Sciences, 2023
- Are we prepared for clinical trials in Charcot-Marie-Tooth disease?Brain Research, 2019
- DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon DegenerationMolecular Neurobiology, 2019
- Disease Modeling and Therapeutic Strategies in CMT2A: State of the ArtMolecular Neurobiology, 2019
- HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neuronsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Regulation of autophagy and mitophagy by nutrient availability and acetylationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014
- Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradationCurrent Opinion in Cell Biology, 2011
- Genotype-Phenotype Correlations in Charcot-Marie-Tooth Disease Type 2 Caused by Mitofusin 2 MutationsArchives of Neurology, 2009
- Mitochondrial coupling defect in Charcot–Marie–Tooth type 2A diseaseAnnals of Neurology, 2007
- Mitochondrial GTPase mitofusin 2 mutation in Charcot?Marie?Tooth neuropathy type 2AHuman Genetics, 2004